NCT03427411View on ClinicalTrials.gov

M7824 in Subjects With HPV Associated Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

February 2, 2021

Study Completion Date

December 31, 2022

Conditions
Human Papilloma VirusCervical CancerOropharyngeal CancerAnal CancerVaginal or Penile Cancer
Interventions
DRUG

M7824

Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03427411 - M7824 in Subjects With HPV Associated Malignancies | Biotech Hunter | Biotech Hunter